Biotricity (Nasdaq: BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, provided selected preliminary financial results for its fiscal third quarter 2024 results, ended December 31, 2023, that include record gross margins and record operational efficiency.

Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, provided an update on the Phase III clinical trial, Flamingo-01. CEO Snehal Patel commented, "While we may have high expectations for the interim analysis midway through the trial, Roche's successful Herceptin and Kadcyla products reduced recurrences by only 50%, while still requiring that all HER2 positive patients be treated. Thus, we believe a similar clinical outcome for Flamingo-01 could occur and could generate similar returns to stakeholders as did Roche's franchise drugs, which at their peak significantly exceeded $5 billion in revenue per year.”

Sharps Technology (Nasdaq: STSS), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique drug delivery solutions around the globe, capitalizing on a growing network of established and new logistics resources.

1847 Holdings (NYSE American: EFSH), a unique holding company that combines the attractive attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, announced that it has restated the financial results of its subsidiary ICU Eyewear Holdings, Inc. ("ICU") for the fiscal years ending December 31, 2021 and December 31, 2022. The financial impact of the restatement on ICU was a decrease in loss from operations of approximately $3.6 million for the year ended December 31, 2022, and an increase in total assets of $642,000, as well as a decrease in accumulated deficit as of December 31, 2022.